StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Amit Seth

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byAmit SethHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.

Entry₹2,300Stated
Target₹2,425
Total upside +5.43% (call closed)
Stop loss₹2,260-1.74% risk
Exit₹2,26019 Aug 2026, 10:45 am
Stop-loss hit-1.74%
Follow Amit Seth for new calls(27% target hit, 158 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 147 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 19 Aug 2026
7 supporting4 neutral2 opposing
Supports the BUY call (7)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·11 Aug · 1w ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·12 Aug · 1w ago

Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising

NewsGoogle News·4 Aug · 2w ago

(opens in new tab)

Glenmark Pharma's India-US Growth Story Intact, Says Motilal Oswal, Maintaining 'Buy' — Check Target Price

NewsNdtv-Profit·4 Aug · 2w ago

(opens in new tab)

Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth

NewsCnbc-Tv18·31 Jul · 3w ago

(opens in new tab)
Neutral / worth noting (4)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 1w ago

(opens in new tab)

Glenmark Pharma Q1 FY27 Results and Brokerage Outlook

NewsGoogle News·4 Aug · 2w ago

(opens in new tab)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 3w ago

(opens in new tab)

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·7 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Amit Seth

Every call and its outcome